ONC - BeiGene, Ltd.

318.07
-5.800   -1.823%

Share volume: 159,375
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$323.87
-5.80
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
51%
Profitability 45%
Dept financing 28%
Liquidity 75%
Performance 58%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.82%
1 Month
15.78%
3 Months
-6.90%
6 Months
0.74%
1 Year
38.76%
2 Year
22.81%
Key data
Stock price
$318.07
P/E Ratio 
117.17
DAY RANGE
$315.70 - $320.57
EPS 
$0.20
52 WEEK RANGE
$218.31 - $385.22
52 WEEK CHANGE
$25.83
MARKET CAP 
33.619 B
YIELD 
N/A
SHARES OUTSTANDING 
222.510 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-06-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$231,804
AVERAGE 30 VOLUME 
$212,312
Company detail
CEO: John V. Oyler
Region: US
Website: beigene.com
Employees: 9,000
IPO year: 2016
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

BeiGene, Ltd. discovers, develops, manufactures, and commercializes medicines for cancer. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma. Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC)

Recent news